Information Provided By: 
Fly News Breaks for February 2, 2017
EW
Feb 2, 2017 | 07:38 EDT
After Edwards Lifesciences reported stronger than expected results, RBC Capital analyst Glenn Novarro notes that the company paused enrollment in its CardiAQ U.S. feasibility study, which also affects the EU development program, according to the analyst. However, he expects the company's U.S. TAVR sales growth to exceed 20% in 2017, and he recommends buying the shares on any weakness while keeping a $116 price target and an Outperform rating on the shares.
News For EW From the Last 2 Days
There are no results for your query EW
